Filana Therapeutics (FLNA) Total Liabilities (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Total Liabilities of $40.3 million for Q2 2026, down 15.01% year-over-year from $47.4 million in Q2 2025, and little changed quarter-over-quarter from $40.2 million in Q1 2026.
Filana Therapeutics (FLNA) Total Liabilities (2010 - 2026) Analysis & Trends
Filana Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $40.3 million for Q2 2026.
- In Q2 2026, Total Liabilities fell 15.01% year-over-year to $40.3 million; the TTM figure through Jun 2026 stood at $40.3 million (down 15.01% YoY), while the FY2025 annual figure was $44.0 million, up 271.56% from the prior year.
- Total Liabilities for Q2 2026 stood at $40.3 million, roughly flat from $40.2 million in the prior quarter.
- The five-year high for Total Liabilities was $243.6 million in Q2 2024, with the low at $7.1 million in Q1 2022.
- The 5-year median for Total Liabilities is $17.7 million (2023), against an average of $44.3 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities soared 1261.1% in 2024, then plunged 91.45% in 2025.
- Filana Therapeutics' Total Liabilities stood at $7.3 million in 2022, then jumped by 94.59% to $14.2 million in 2023, then declined by 16.67% to $11.8 million in 2024, then soared by 271.56% to $44.0 million in 2025, then retreated by 8.32% to $40.3 million in 2026.
- Business Quant data shows FLNA's Total Liabilities at $40.3 million in Q2 2026, $40.2 million in Q1 2026, and $44.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Filana Therapeutics | 45.29 Mn | 45.29 Mn | - | 40.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.29 Mn |
| Mar 31, 2026 | 40.23 Mn |
| Dec 31, 2025 | 43.95 Mn |
| Sep 30, 2025 | 48.17 Mn |
| Jun 30, 2025 | 47.41 Mn |
| Mar 31, 2025 | 13.32 Mn |
| Dec 31, 2024 | 11.83 Mn |
| Sep 30, 2024 | 57.11 Mn |
| Jun 30, 2024 | 243.57 Mn |
| Mar 31, 2024 | 155.72 Mn |
| Dec 31, 2023 | 14.20 Mn |
| Sep 30, 2023 | 17.41 Mn |
| Jun 30, 2023 | 17.90 Mn |
| Mar 31, 2023 | 14.11 Mn |
| Dec 31, 2022 | 7.30 Mn |
| Sep 30, 2022 | 8.57 Mn |
| Jun 30, 2022 | 9.01 Mn |
| Mar 31, 2022 | 7.10 Mn |
| Dec 31, 2021 | 12.87 Mn |
| Sep 30, 2021 | 6.68 Mn |